Five people may have died in recent years after drinking Monster Energy, a popular energy drink that is high in caffeine, according to incident reports recently released by the Food and Drug Administration.
Monster Beverage is sinking after reports that 5 people may have died after drinking the popular Monster energy drink, with CNBC's Herb Greenberg. Bill Chapell, Suntrust Robinson Humphrey analyst, weighs in.
Monster Beverage is down about 9 percent today on reports that 5 people may have died after drinking the popular Monster energy drink, reports CNBC's Jackie DeAngelis.
Discussing whether an Iranian currency collapse could lead to a revolution, with Peter Brookes, former Deputy Assistant Secretary of Defense, and Don Luskin, Trend Macro; and America's warriors are being denied the right to vote, with Kyndra Rotunda, Military Voter Protection Project.
The FDA recalled a contaminated batch of a steroid drug given by spinal injection for back pain, and American Airlines is grounding all 48 of its Boeing 757 aircrafts as they fix the seat lock mechanism that was the cause of seats coming loose, reports CNBC's Seema Mody.
The average rate on the 30-year fixed mortgage held steady this week, staying slightly above the lowest level on record.
The headlines on Monster Beverage are all about health concerns as at least one state’s attorney general investigates its products. But there may be something even bigger: Monster’s growth may be showing signs of peaking.
The first rule of insider trading: Don’t talk about insider trading—or do a lot of Internet searches about it.
The marketplace for narcotics isn’t what it used to be. Read ahead to see a list of dangerous drugs that are legal in many American states.
CNBC's Jackie DeAngelis and Jane Wells report on the agriculture department's response to widespread drought conditions, Merck's new osteoporosis drug, and the buyer of Edvard Munch's "The Scream."
Find out which second-quarter top performer got the most votes.
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
Peter Madoff, the younger brother of Ponzi swindler Bernie Madoff, was arrested this morning and will appear in court later in the day as part of a process that will see him serve 10 years in prison for his role in the swindle.
Jack Lief, Arena Pharmaceuticals CEO, discusses what the drug-maker's new anti-obesity drug will mean for its bottom-line, with CNBC's Seema Mody.
Newly released documents reveal that Pfizer presented a study falsely claiming that its arthritis drug, Celebrex, was safer on the stomach than competing drugs, the New York Times reports.
U.S. regulators, retailers and manufacturers are growing increasingly concerned that a surge in the number of products being recalled is resulting in "fatigue" by the public — increasing the chance that consumers could ignore or miss a recall that could ultimately endanger their health, USA Today reports.
Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.
If Americans ever eat genetically engineered fast-growing salmon, it might be because of a Soviet biologist turned oligarch turned government minister turned fish farming entrepreneur, the New York Times reports.
CNBC's Seema Mody reports on the latest details of the FDA advisory panel's review of Arena Pharmaceuticals' anti-obesity drug.
Ten days after the FDA sent warning letters to manufacturers of supplements with DMAA in it, the nation’s largest supplement retailers still have the product on the shelves.